Join Growin Stock Community!

Hims & hers health, inc.HIMS.US Overview

US StockConsumer Defensive
(No presentation for HIMS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HIMS AI Insights

HIMS Overall Performance

HIMS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HIMS Recent Performance

-4.35%

Hims & hers health, inc.

0.44%

Avg of Sector

0.49%

S&P500

HIMS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HIMS Key Information

HIMS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HIMS Profile

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

Price of HIMS

HIMS Related Articles

Hims & Hers ( Hims ) 財報分析 2025 Q3 – 會員成長超預期，盤後股價上漲
Nov 04, 2025Financial Report Analysis

Hims & Hers ( Hims ) 財報分析 2025 Q3 – 會員成長超預期，盤後股價上漲

Hims & Hers ( Hims ) 於美國時間 08/04 公布 2025 Q2 (FY25Q2) 財報，展現了顯著的營收成長，儘管部分指標未達分析師預期，導致盤後股價下跌 13%，但公司對於未來展望仍保持信心，究竟本季度 HIMS 表現如何呢? HIMS 股價會受到影響嗎? Hims & Hers ( Hims ) 在第二季度的財報中營收年增驚人的 72.6% 達到 5.45 億美元，但略低分析師預期的 5.5 億美元，每股盈餘則是 0.17 美元高過市場預期的 0.15 美元。 線上收入作為 HIMS 的主要收入來源，這一季度的收入大幅年增 75% 來到 5.36 億美元，主要由「使用個人化治療計畫的訂閱者強勁增長」所驅動。CEO 也強調，HIMS 正在提供數百萬人期待的「客製化、高品質的護理」，這也推動了業務的發展。 批發業務主要包括向實體零售商供應非處方保健產品，本季年減 10% 為 795 萬美元，但因訂閱型業務（online subscription）持續增長，公司正逐漸轉向重視訂閱模式，批發的營收比重不斷下降，也不是投資人重點關心的項目。   這一季度訂閱用戶數達到 244 萬人，較前一季度的 237 萬人有所增加。這反映了其遠距醫療服務的市場滲透率和用戶基礎的持續擴大。 CEO 表示，HIMS 正進入一個令人興奮的成長期，將進入新的、高影響力的專業領域，吸引數百萬有護理需求的人進入市場期望透過擴展服務範圍，將平台從解決單一問題轉變為客戶能主動管理整體健康的平台。這暗示了未來將推出更多元的服務來深化用戶在平台上的價值。 CFO Yemi Okupe提到，公司將投資於加強藥房的客製化基礎設施、擴展實驗室檢測能力以進一步量身定制護理，並在關鍵市場擴大國際業務。這些投資將支持其核心業務的長期成長和服務深度。 但得注意的是，Q2 的營運現金流為負 1,910 萬美元，相較於去年的 5,360 萬美元有所下降，自由現金流也呈現負 6,940 萬美元，大幅低於去年同期的 4,760 萬美元 ，主要來自在本季度投入了較多資金於營運和投資活動，導致現金流出。   HIMS 在下一季度預期營收將介於 5.7 億美元至 5.9 億美元之間，與分析師約 5.8 億美元的預估接近，全全年營收預期則是介於 23 億美元至 24 億美元之間。在前陣子 HIMS 也因市場曾擔憂官方 GLP-1 藥物短缺結束可能對 HIMS 的銷售造成衝擊，但財報中並未直接提及其影響。   根據 12 位分析師的預測，分析師預測 HIMS 在未來一年內之股價目標價為 48.36 美元，最大值為 85 美元，最小值則是 28 美元，分析師建議持有 HIMS 的股票，截至美國時間 2025 年 8 月 04 日的 收盤價 63.85 美元計算，目前高於目標 26%。   目前 HIMS 籌碼分數為 3 分，主因為籌碼較為集中穩定，但近一季有籌碼流出的跡象。 近期加碼 HIMS 的機構有 164 間，建倉機構 114 間，然而減碼機構為 160 間，清倉機構為 74  間。從 Growin 提供的 10 間比較密集受到關注的大型機構數據， 本季度買入的機構為橋水基金和文藝復興基金。 下圖為 HIMS 的股價營收比 PS Ratio 趨勢圖，可以發現目前 HIMS 處於接近歷史高估值的位置，並且也遠遠大於過去五年來的平均。表示市場對於 HIMS 的未來發展有著極高的展望，以一間剛獲利不久且營收年增長能達到 70% 的公司來說，目前的估值或許並不昂貴，並且也搭上了最新的 AI 浪潮，也使未來展望有更多說故事的空間。   再以下圖來看，HIMS 的未來營收預估都能達到約 20% 的成長，2025 更是預期有驚人的 59%，這也是市場能接受 HIMS 高估值的原因，但缺點則是股價波動會較為劇烈。 總體而言，HIMS 的關鍵業務展現出強勁的營收成長和盈利能力，主要得益於其訂閱模式下的個人化護理服務擴張。儘管本季度營生略低於預期且短期內現金流為負，但公司對未來的增長和服務擴展持樂觀態度，並計畫透過戰略性投資來深化其平台價值和市場覆蓋，仍然可以期待後續 HIMS 的表現。   好消息來啦 🎉 Growin 投資交流社群正式上線！  不論你是投資新手還是資深老手，都歡迎加入 Growin 的 Discord 投資交流頻道，與投資同好們一起交流市場趨勢、個股資訊，並獲取第一手的投資洞察！ 歡迎加入，一起在投資的道路上成長茁壯！  🚀  
HIMS 是做什麼的？深入解析 HIMS 核心業務、盈利模式與未來前景
Oct 01, 2025Industry

HIMS 是做什麼的？深入解析 HIMS 核心業務、盈利模式與未來前景

Hims & Hers Health（HIMS）主打遠距醫療與健康自費市場，讓消費者能直接透過官網或 App 完成看診問卷、醫師評估、處方配藥與線上購藥訂閱。
【2025/09/04 每日美股市場資訊】科技股領漲，美股週三漲跌互現，Alphabet 飆漲 9%
Sep 04, 2025Daily News

【2025/09/04 每日美股市場資訊】科技股領漲，美股週三漲跌互現，Alphabet 飆漲 9%

週三美股主要指數走勢分化，納斯達克指數上漲 1%、S&P 500 指數收高，受惠於 Alphabet（GOOGL）股價大漲，以及市場對本月美聯儲可能降息的樂觀情緒。道瓊斯工業指數則小幅收低，主要受到波音（BA）下跌 2.1% 的拖累。 Alphabet 飆升 9.1%，此前美國法官裁定，允許 Google 繼續掌控 Chrome 瀏覽器與 Android 系統，但禁止其與設備製造商和瀏覽器開發商簽訂某些排他性協議。該裁決有效避免了 Google 被強制分拆的風險，提振了市場信心。 蘋果（AAPL）也上漲 3.8%，原因是谷歌仍被允許向蘋果等合作夥伴支付費用，以確保其搜索引擎為預設選項。 整體而言，科技股成為推動 S&P 500 與納指上漲的主要動力，而波音等工業股走弱使得道指表現落後。   美國勞工統計局（BLS）週三公佈數據顯示，7 月美國職位空缺降至 718 萬個，不僅低於市場預期的 738 萬個，也創下近 10 個月新低，顯示企業招聘態度趨於謹慎。這反映出在政策不確定性升溫的背景下，勞動力需求正在逐步減弱。 從行業來看，醫療保健、零售貿易、休閒與酒店業是職位空缺下降的主要來源。其中，醫療保健領域的空缺降至 2021 年以來最低水平，格外引人關注。作為近年支撐就業增長的關鍵部門，醫療與社會援助職位需求的下滑，可能對未來整體就業市場構成壓力。 Renaissance Macro Research 首席經濟研究員 Neil Dutta 表示：「職位空缺的下降主要集中在醫療及社會援助，以及州和地方政府部門。這些通常不隨經濟週期波動的行業若持續走弱，將對美國就業增長造成顯著影響。」   伯恩斯坦分析師最新報告指出，台積電（TSM）將顯著受惠於人工智慧熱潮，並上調公司目標價。該行將台積電目標價由 $1,260 調升至 $1,444，台積電 ADR 則由 249 美元上調至 290 美元，並維持「優於大盤」評級。 分析師認為，強勁的 AI 與非 AI 需求將推動台積電 2025 年收入增長至少 33%，高於公司預期的 30%。同時，在外匯逆風減弱與 AI 應用快速普及的推動下，台積電的獲利有望超過市場共識，凸顯其在晶片代工領域的主導地位。 雖然 2026 年與 2027 年資本支出預料將增加，但由於台積電持續採用 設備重複利用策略，可望減輕對盈利的壓力。此外，該公司有望調高高階晶片的價格，以抵銷更高的投資與不利的匯率因素。 整體來看，伯恩斯坦預計台積電不僅能維持全球晶片代工龍頭地位，更將是 AI 半導體產業最大贏家之一。   Snowflake（SNOW）週三盤後股價下跌 2.7%，原因是公司宣布 首席財務官 Mike Scarpelli 將於 9 月 22 日退休。 為確保平穩過渡，Snowflake 指定來自 GitLab 的 Brian Robins 出任新任 CFO，接手 Scarpelli 的財務管理與策略規劃職責。Scarpelli 將在過渡期繼續留任，之後轉任公司顧問角色。 Snowflake 執行長 Sridhar Ramaswamy 在聲明中表示：「我們對 Brian 接任 CFO 後公司下一階段的增長充滿信心。」 Robins 擁有豐富的財務管理經驗，自 2020 年起擔任 GitLab CFO，過去亦曾在 Sisense、Cylance、AlienVault 及 Verisign 擔任高階財務職務，被視為能助力 Snowflake 在 AI 數據雲領域持續擴張的重要人選。   Hims & Hers Health（HIMS）週三股價上漲 7%，受惠於一項有利的法律裁決，緩解了市場對大型製藥公司訴訟風險的憂慮。 美國一名聯邦法官駁回了 禮來（LLY）對 Willow Health 的訴訟。後者是一家與 Hims 類似的遠程醫療提供商，該案件涉及複合版本減肥藥的銷售。裁決被視為對大藥廠試圖限制 GLP-1 藥物複製與複合製劑的重要挫敗。 這一進展對 Hims 至關重要。雖然 FDA 已在 2025 年初宣布司美格魯肽（semaglutide）和 替爾澤肽（tirzepatide）藥物短缺問題獲得解決，但 Hims 仍依循聯邦指導方針，向患者提供定制化複合版本。此舉使其在減肥藥市場上持續保持競爭力，也讓投資人對公司未來增長的信心進一步增強。   🇹🇼 台股  

HIMS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HIMS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.59
PE Ratio (TTM)
29.49
Forward PE
12.50
PS Ratio (TTM)
1.61
PB Ratio
6.20
Price-to-FCF
64.75
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.84%
Net Margin
5.47%
Revenue Growth (YoY)
59.00%
Profit Growth (YoY)
47.76%
3-Year Revenue Growth
54.60%
3-Year Profit Growth
49.75%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.59
PE Ratio (TTM)
29.49
Forward PE
12.50
PS Ratio (TTM)
1.61
PB Ratio
6.20
Price-to-FCF
64.75
Gross Margin
73.84%
Net Margin
5.47%
Revenue Growth (YoY)
59.00%
Profit Growth (YoY)
47.76%
3-Year Revenue Growth
54.60%
3-Year Profit Growth
49.75%

  • When is HIMS's latest earnings report released?

    The most recent financial report for Hims & hers health, inc. (HIMS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HIMS's short-term business performance and financial health. For the latest updates on HIMS's earnings releases, visit this page regularly.

  • Where does HIMS fall in the P/E River chart?

    According to historical valuation range analysis, Hims & hers health, inc. (HIMS)'s current price-to-earnings (P/E) ratio is 89.47, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of HIMS?

    According to the latest financial report, Hims & hers health, inc. (HIMS) reported an Operating Profit of 9.19M with an Operating Margin of 1.49% this period, representing a decline of 50.6% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HIMS's revenue growth?

    In the latest financial report, Hims & hers health, inc. (HIMS) announced revenue of 617.82M, with a Year-Over-Year growth rate of 28.41%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does HIMS have?

    As of the end of the reporting period, Hims & hers health, inc. (HIMS) had total debt of 1.12B, with a debt ratio of 0.52. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HIMS have?

    At the end of the period, Hims & hers health, inc. (HIMS) held Total Cash and Cash Equivalents of 228.62M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HIMS go with three margins increasing?

    In the latest report, Hims & hers health, inc. (HIMS) achieved the “three margins increasing” benchmark, with a gross margin of 71.94%%, operating margin of 1.49%%, and net margin of 3.33%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HIMS's profit trajectory and future growth potential.

  • Is HIMS's EPS continuing to grow?

    According to the past four quarterly reports, Hims & hers health, inc. (HIMS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HIMS?

    Hims & hers health, inc. (HIMS)'s Free Cash Flow (FCF) for the period is -9.75M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 116.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of HIMS?

    The latest valuation data shows Hims & hers health, inc. (HIMS) has a Price-To-Earnings (PE) ratio of 89.47 and a Price/Earnings-To-Growth (PEG) ratio of 3.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.